Thompson Davis & CO. Inc. Has $1 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Thompson Davis & CO. Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 33.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,715 shares of the company’s stock after selling 860 shares during the quarter. Eli Lilly and Company makes up approximately 0.9% of Thompson Davis & CO. Inc.’s holdings, making the stock its 14th biggest holding. Thompson Davis & CO. Inc.’s holdings in Eli Lilly and Company were worth $1,000,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Simon Quick Advisors LLC increased its position in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $363,000. Terril Brothers Inc. increased its position in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after acquiring an additional 429 shares in the last quarter. Hartline Investment Corp increased its position in Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after acquiring an additional 248 shares in the last quarter. Finally, Meritage Portfolio Management increased its position in Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after acquiring an additional 1,208 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $731.55.

Eli Lilly and Company Stock Up 6.0 %

Shares of LLY stock traded up $44.36 during trading on Tuesday, reaching $781.56. The company’s stock had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. The company has a market cap of $742.61 billion, a price-to-earnings ratio of 134.75, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a one year low of $392.26 and a one year high of $800.78. The business has a fifty day moving average price of $761.41 and a 200-day moving average price of $669.21. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.09 earnings per share. Analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.